Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, we just had a big run. Give it time to rest and consolidate before the next leg up. AIMHO, of course!
Good luck!
-Fritz
Percy, they should have a lot to talk about at Jefferies this year!
Good luck!
-Fritz
Nice chart by MKA. Thanks for posting that. The inverse head and shoulders is beautifully set up. Money flow is positive. Overall a very compelling chart. My only quibble would be that the neckline would be set at around $.17. Close over that and we're off to the races.
Good luck!
-Fritz
That's if you accept twitter tweets from a crack team of 20 somethings as a "news stream". FXCM just cancelled their subscription to the more widely acceptable Thomson/Reuters squawkbox and news stream so you are left with the above. Good luck with that as your trading resource.
-Fritz
Halozyme's Phase 2 Insulin-PH20 Study Demonstrates Faster Insulin Absorption and Superior Glucose Control in Type 1 Diabetic Patients
-- Insulin-PH20 combination significantly reduced post-meal blood glucose concentration relative to treatment target resulting in reduced hyperglycemia --
SAN DIEGO--(BUSINESS WIRE)--Jun. 6, 2009-- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (PH20) with Humalog® (insulin lispro), a mealtime insulin analog. Study results also showed a significant reduction in postprandial blood glucose levels following administration of a standardized test meal, with improvements in both peak glycemic response and total hyperglycemic exposure compared to Humalog alone. Mean glucose levels after the meal challenge remained within current treatment targets throughout the eight hour post meal observation period. The company presented these results at the American Diabetes Association (ADA) 69th Scientific Sessions today in New Orleans.
In addition, Halozyme announced that its first treatment study with three times per day mealtime dosing of Insulin-PH20 in type 1 diabetic patients began in May, ahead of the company’s previous guidance for a fourth quarter 2009 start date.
“The faster and shorter blood insulin concentration profile observed for Humalog plus PH20 in this study conducted in type 1 diabetic patients confirms our previous findings seen in healthy volunteers. The shift in the pharmacokinetics of Humalog with PH20 confers a more physiologic insulin profile and results in lower hyperglycemia after a meal,” stated Jonathan Lim, M.D., Halozyme’s president & CEO. “A more rapidly acting insulin may lead to such patient benefits as fewer incidences of hypoglycemia, insulin dose reduction, greater patient convenience, and less weight gain.” The goal of Halozyme’s Insulin-PH20 program is to develop a rapid and short-acting insulin product that would more closely mimic the mealtime insulin release that occurs in non-diabetics that could lead to improved treatment for diabetes patients.
ADA Presentation Focused on Humalog, Humulin® R Data to Come
This Phase 2 study investigated the pharmacokinetics (PK) and glucodynamics (GD) of Humalog and Humulin R with and without Halozyme’s PH20 enzyme in 21 type 1 diabetic patients. The results presented today at ADA are for the Humalog portion of the study. Additional results from this study for Humulin R alone and in combination with PH20 have been accepted for presentation at the European Association for the Study of Diabetes (EASD) meeting in the fall.
After fasting and refraining from insulin treatment for 12 hours, patients were titrated to a stabilized 100 mg/dL glucose target with intravenous (IV) glucose and/or insulin. The same optimized dose of insulin lispro (mean 5.7 IU) with and without PH20 enzyme was injected subcutaneously (SC) immediately before a standard meal of 12 oz. Ensure and plasma insulin and glucose concentrations were monitored for 8 hours. The primary endpoint was a PK measure of area under the curve (AUC0-60) for insulin during the first 60 minutes after the SC injection. Secondary endpoints included other PK measures, glucose excursion outside of the selected target range and hypoglycemia.
Key Findings Described in the Poster Presentation Today
This clinical trial met the primary endpoint and demonstrated faster systemic insulin absorption, greater peak exposure, greater early and reduced late postprandial exposure, and a significant reduction in postprandial hyperglycemia without significant change in hypoglycemia risk. All injections were well tolerated.
* The addition of PH20 significantly reduced postprandial glucose by 40% during the first four hours after administration as measured by 147 mg/dL for the lispro-PH20 combination compared to 174 for lispro alone (p = 0.002). This resulted in less hyperglycemia for the combination treatment without additional hypoglycemia.
* PH20 combined with Humalog increased the AUC0-60 as a percent of total insulin exposure from 40% to 59 % (p < 0.0001) and to 149% of Humalog alone for the combination treatment. The addition of PH20 significantly increased early insulin absorption during the first 60 minutes after injection.
* The time to maximum (tmax) insulin concentration with co-administration of PH20 was reduced for Humalog by 19 minutes (p < 0.0001) from 49 to 30 minutes. This indicates faster insulin absorption with PH20.
* Co-administration of PH20 increased maximum insulin concentration (Cmax) for Humalog by 38% (p = 0.0007) from 45 to 62 pM/IU.
Review of Insulin-PH20 Clinical Trials
A number of clinical trials investigating Halozyme’s Insulin-PH20 are currently underway and more trials are planned.
* Type 1 treatment study – This Phase 2 clinical trial, which began in May 2009, will compare regular insulin (non-analog insulin) + PH20 to lispro alone. After a one month observation period that includes dose optimization, patients will be randomized to regular insulin + PH20 or lispro and treated for three months. At the end of three months, patients will crossover to the other study treatment for another three months. The study will evaluate safety and efficacy. Roughly 20 patients will be enrolled and results should be available in 3Q2010. Patients will self administer their insulin on an out-patient basis. ClinicalTrials.gov Identifier: NCT00883558.
* Dose ranging PK study – This Phase 1 clinical trial began in 4Q08 and will determine the optimal insulin/PH20 ratios. Humalog and Humulin R will be tested with and without PH20 across a range of doses of insulin and concentrations of both PH20 and insulin in this euglycemic glucose clamp study and various PK parameters will be measured in approximately 40 healthy subjects. Results of the study will be used to optimize dosing in future trials. ClinicalTrials.gov Identifier: NCT00803972.
* Intra-subject variability – This Phase 1 trial started in 1Q09 and will test regular insulin + PH20, lispro + PH20 and lispro alone. It is a euglycemic glucose clamp study in 18 healthy subjects and will measure PK and GD parameters over eight hours on two separate administrations with the same test dose of each study drug. Information regarding the consistency of insulin absorption and action will be collected and results are expected by the end of the year. ClinicalTrials.gov Identifier: NCT00862849.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche’s biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID™. The product candidates in Halozyme’s research pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, (i) statements concerning the efficacy and benefits of insulin plus PH20 combinations, (ii) clinical trial results and the conclusions drawn from such trials, and (iii) the initiation and completion of clinical trials) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.
Source: Halozyme Therapeutics, Inc.
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1296808&highlight=
Halozyme
Robert H. Uhl
Senior Director, Investor Relations
858-704-8264
ruhl@halozyme.com
Percy, it sure didn't deter this buyer who has been accumulating
relentlessly over the past week. This guy will not be denied. At this point I'm just standing back in wonder watching him make his move. One has got to be curious as to what he knows, eh?
Good luck to him and us! LOL!
-Fritz
Yes it's sure to mess up my chart tomorrow. LOL!
Oh, well, it was getting a bit frothy anyway.
There were sure some damned determined buyers out there these past few sessions. Makes you wonder what it is they know...
I find it interesting that the buying was not hampered by the general market downdrafts today. Even when the Dow was down about 130 pts HALO actually was near the HOD. That, in my opinion, is a new and interesting development. Stay tuned...
Good luck!
-Fritz
Halozyme Deprioritizes Bisphosphonate Program to Reallocate Resources to More Commercially Attractive Internal Programs
SAN DIEGO--(BUSINESS WIRE)--Jun. 3, 2009-- Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced deprioritization of its Bisphosphonate-PH20 Phase 1 program for osteoporosis. Halozyme management has decided to deploy resources to its other more commercially attractive internal programs in endocrinology, oncology, and dermatology.
Preclinical data presented by Halozyme Therapeutics at the 2008 American Association of Cancer Research meeting noted that bisphosphonates formulated for intravenous administration cause severe injection site reactions (ISRs) when administered locally. While Halozyme successfully completed dosing for eight cohorts of varying concentrations of bisphosphonate in combination with PH20, the occurrence of mild to moderate ISRs at commercially attractive volumes and dosing schedules exceeded the company’s predefined benchmarks for moving forward.
“We have a rigorous portfolio management process designed to support the development and commercialization of first in class or best in class products,” stated Jonathan Lim, M.D., Halozyme’s president and CEO. “Based on this open label study, the results do not justify further development of Bisphosphonate-PH20 for osteoporosis. We will reallocate our resources to more commercially attractive product candidates in Halozyme’s portfolio.”
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche’s biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID™. The product candidates in Halozyme’s research pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements relating to clinical trial results and conclusions, the company’s portfolio management process and the reallocation of corporate assets to other programs) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.
Source: Halozyme Therapeutics, Inc.
Halozyme
Robert H. Uhl
Senior Director, Investor Relations
858-704-8264
ruhl@halozyme.com
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1295922&highlight=
Say goodby to the down trend.
A month ago I wrote:
Nice chart. The inverse head and shoulders pattern is on the right. Left shoulder marked by $6.41 high, the right by the $6.23 high. If we breakout over $6.41 we're off to the races, IMHO. A close above $7.00 will pierce that down trend line thereby changing the whole look of that chart. Stay tuned.
Linking back to ReadThisNow's chart, I think we can wave goodby to that downtrending channel. As I've noted in recent weeks, HALO has the wind at its back.
Good luck!
-Fritz
HALO Chart: Breakout
The healthy stair-step pattern continues. After each high we get a couple of weeks of consolidation followed by another move upwards. Today we were treated to a nice PR which highlighted old news but brought forth a considerable amount of volume. We pierced the price channel and with all that volume it's unlikely that we will drift lower until we move closer to $7.50 at which point we can expect a pause to consolidate. It was nice to see the price hold up right into the close. Money flow is strong. There were some determined buyers today. We do seem to be hitched to the greater winds of the overall market which I find interesting. I don't think we've had many green days when the S&P is red. Frankly I'm not sure what to make of that little phenomenon. But still a beautiful and healthy chart. Churning uphill in low gear prevents any strong retracements. All in all a very significant day, IMHO.
Good luck!
-Fritz
Saudis Warn Of $150/Barrel Oil Within Three Years - FT Tokyo, May 26. According to the article, Saudi OilMin Naimi says the world was heading for a fresh spike in crude oil prices after the current phase of faltering demand and lower prices is past us. He made this comment as the G8 energy summit wrapped-up a two day meeting. Most of the participants called for more investment to boost production despite the current credit crisis. Although maybe still premature at this time, crude oil has been trading a bit higher as of late as if to discount an upcoming economic bottom. June crude oil futures closed at $61.67 Friday and GLOBEX trading saw the contract up to the $62.10 level yesterday.
Oil about to touch $60.
Personally, I'm glad they are up front on the Baxter issue. This is infinitely more preferable to papering over an obvious error. I am sick to death of lying CEOs so the clarity of HALO managements communications are very much appreciated by this investor.
Mistakes are made in every company. Some are irreparable while some are good learning experiences. These days one need not look too far to see many instances of the former. Here we have the latter, and IMHO these lessons will almost certainly be brought to bear in the critical months ahead when even larger, more consequential deals are in the offing.
Good luck!
-Fritz
Cash Flow (10bagger, I'm surprised you didn't mention this):
Cash Flow from Operating Activities
For the three months ended March 31, 2009, cash provided by operating activities was $3.9 million as compared to cash used in operating activities for the same prior year period of $0.5 million.
In other words, positive cash flow from operations is $3.9 million versus negative cash flow of half a million in the same Q last year. A major step, IMHO.
-Fritz
Cash on Hand:
As of March 31, 2009, our cash and cash equivalents were $6.4 million, which includes restricted cash of $0.1 million. Cash and cash equivalents were $2.6 million including restricted cash of $0.1 million as of December 31, 2008. This increase was largely due to collection of outstanding accounts receivable. Management believes that we have adequate capital resources when combined with our cash position and cash flow from operations to meet current operating requirements for the 12 months ending March 31, 2010.
Mark that under "Lessons Learned".
Interesting that management has, for the first time to my knowledge, publicly criticized Baxter for its lethargy. The good news is we can assume that "once bitten, twice shy", HALO's deal makers will benefit from this experience in crafting a more benefical deal next time around.
Good luck!
-Fritz
io, how do you see the pact trial at this point?
I have my doubts after having been long gnvc for a number of years. Also, last I checked, the company is on thin ice financially. Your take?
Good luck!
-Fritz
I'm with you on that. I've been long this stock since late 2006 when it was known as HTI and sold OTC. I'm not a trader so I missed many opportunities to make short term coin here. I've always been of the opinion that the minute I sell my stake for a 50 cent gain the news will inevitably break that Kirk and Co. sold the whole operation for $30 bucks a share. LOL! I'm confident, though, that I will be well rewarded for my patience.
Good luck!
-Fritz
halofan, my guess is that some folks saw an opportunity to take some profits and did. Others may even go so far as to take their halo capital and move it to more active arenas like the financials. All in a days work but nothing nefarious IMHO.
Good luck!
-Fritz
thanks for the update, spec.
Good luck!
-Fritz
That comment is based upon a distinct lack of due diligence.
Have you at least looked at the O/S figures over, say, the past year?
I didn't think so.
-Fritz
Brokers don't use "global feeds". They have their own counter parties, i.e., larger banks who deal in Forex. There is no central exchange as you imply.
-Fritz
It's erroneous to refer to the general market since the ONLY "person" you are trading with is your broker. When you press the buy button he is the seller. When you press sell, he is the buyer.
-Fritz
Multiply your $5 times the number of other stops likely to be found in that range. Smells like easy money to me.
-Fritz
If your chart shows a general directional trend but is interrupted by a seemingly random spike up or down 20 or 30 pips, only to resume the earlier trend, then you can generally assume that your broker is stop hunting. They have the motive, the means and the opportunity, so why wouldn't they?
-Fritz
Be aware that your broker is the sole source of price feeds to you, so he can show you a price feed that suits his purposes. (Unlike the stock market, forex has no centralized exchange. Your broker acts as your sole counter party. This is no secret. Read the fine print of your brokerage agreement.) Thus, if there are enough stops set at a given level to get his attention, he will make it happen. The more this happens to you the more you will realize that it is no coincidence.
Good luck!
-Fritz
It's no accident. Your friendly forex broker knows exactly where your stops are and will hunt them down every time.
-Fritz
Halozyme to Host Conference Call and Webcast on May 8 to Discuss First Quarter 2009 Financial Results
SAN DIEGO, May 01, 2009 (BUSINESS WIRE) -- Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced that it plans to report its first quarter 2009 financial results on Friday, May 8, 2009 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PST (11:00 a.m. EST), which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the first quarter 2009 and provide a product pipeline update.
To participate by telephone please dial 888-256-9044 for domestic callers or 706-643-5585 for international callers and provide the conference ID # 97698199. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's Web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme's Web site for 30 days. A telephone replay will be available by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID(TM). The product candidates in Halozyme's research pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
SOURCE: Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc.
Robert H. Uhl
Senior Director, Investor Relations
858-704-8264
ruhl@halozyme.com
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1283182&highlight=
Yep, that's what he was likely looking at. Good find, Rod and thanks for sharing your spade work. Vaino may have gotten a heads-up from someone "in the know" pointing him in that direction. Looks like the study will be short and sweet, also, confirming his time frame estimates for income.
Overall, HALO has the wind at its back now. Feels good after the tough sledding we have had to endure since the Morgan-Joseph knife in the back way back when.
Good luck!
-Fritz
Rod, what do you make of the clinicaltrials.gov comment from Vaino?
-Fritz
Thanks for that heads-up, Percy. Any word on their price targets?
-Fritz
Uncle: I was assuming 17 mil annually based on info in the 10Q.
14 illion plus 3 million added due to absence of one time charges.
Regards,
-Fritz
A 49% margin would be great. The last 10Q, however, states margins were between 30-39% (if memory serves).
Multiples in this day and age are going to be lower as well, but that depends on growth rates so I would not necessarily disagree with you there.
-Fritz
You might also note that $7.00 is not that far off.
Good luck!
-Fritz
Brass tacks on valuation.
Now that the mojo is back on this board I'd like to focus on actual valuation vs. the typical "too the moon!!!!" comments that one encounters on msg boards.
My estimation is annualized earnings of $.03 per share now that the one off expenses are behind us. (Assumptions: $17 million gross revenue and 30% margin.) A fair and reasonable multiple in these current market conditions would likely be a factor of 10.
That puts us at a pps of $.30 IMHO.
Thoughts?
Good luck!
-Fritz
Nice chart. The inverse head and shoulders pattern is on the right. Left shoulder marked by $6.41 high, the right by the $6.23 high. If we breakout over $6.41 we're off to the races, IMHO. A close above $7.00 will pierce that down trend line thereby changing the whole look of that chart. Stay tuned.
-Fritz
HALO Chart demonstrating inverse head and shoulders pattern
Added to our recent discussions on T/A, it is heartening to observe the most recent bullish pattern. By this I mean the inverse head and shoulders pattern. The HALO chart today shows a classic inverse head and shoulders, including the notable increase in volume over the past three days.
Here is a good discussion on the topic. They might as well have posted today's HALO chart in this article. LOL!
http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:chart_patterns:head_and_shoulders_b
Interesting find, there, Rod.
Here is a link displaying those AH trades.
http://ih.advfn.com/p.php?pid=trades&cb=1240629949&symbol=N^HALO&java_vm=sun&fp=10.0.22
Hard to say what to make of it. Probably just some poor sap who forgot to place a limit order. Looks like less than 4k shares were bought at the higher ask, while the majority, about 9k shares, went for $6.20 or less.
As for T/A I agree the chart is setting up nicely and so far is validating my observations posted earlier this month, and which I quote below:
Thirsday, April 2, 2009
Today's chart contains a good example of a bullish engulfing candle (see ibox). My technical analysis musings have been laughable in recent months but I've always felt that these charts
are useful only in normal environments and far less so in Crazy Town such as we have found ourselves in since last fall. So with that caveat I mention the bullish formation with great trepidation, but if the G-20 meetings don't make Wall Street and other investors suicidal this week then we may see a very nice move from HALO in April. Going back to some of my T/A comments in the past month or two, I was predicting a strong move up to the high single digits with an assault on 10 not out of the question. These thoughts were belied by, IMHO, macro economic events which essentially had nothing to do with HALO but in the end had everything to do with the progress of the stock price. If the S&P500 maintains a firm footing then I reiterate my earlier prognostications.
Good luck!
-Fritz
Weds., April 8th
Second, I do agree that the low $6.00 range is a short term resistance point. The key to your observation, IMHO, is the phrase "in the last several months". A look at a longer term chart shows a little more historical perspective, such as the one I include below. After we clear the $6.41 resistance point there is no major hurdle until 2 dollars later at the low $8.00.
Looking at the chart below, since December we are in a bullish up trend. We tested the low sixes in January and pulled back in a classic retracement of about 50%. We are now in another ascending channel beginning at the retracement low of $3.93 and are now challenging resistance once again starting in early March. Nothing goes straight up and this is a very healthy chart, IMHO. The money flow indicators are positive, indicating buying interest outweighs the sellers.
Profit taking at certain levels is inevitable and that's a large part of the pull backs. Another reason, that I've mentioned before, is the macro environment in which we find ourselves. Buy and hold is out of favor and you hear a constant refrain that we are in a "trader's market". This causes some instability as well since the "strong hands" that typically stabilize a particular stock have been beaten senseless by the events of the last 9 months. If the overall market finds some degree of secure footing then that will inevitably help HALO crash through resistance points because there will be fewer sellers offering their shares for short term profit taking.
Thirdly, I also agree with you that fundamentals are primary and, in fact, are the true driver in any investment. In that regard, I believe we are in a very good position.
In the mean time let's bounce off of that middle bollinger band and aim for $6.50 by the end of the month.
Good luck!
-Fritz
Kurt Gustofson option grant filed today.
Exercise price $5.94. He'd better get to work!
-Fritz
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-SECText&TEXT=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvZmlsaW5nLnhtbD9yZXBvPXRlbmsmaXBhZ2U9NjI3OTkyNSZhdHRhY2g9T04mc1hCUkw9MQ%3d%3d